Vectura licenses formulation patents to GSK for £20 million plus royalties
This article was originally published in Scrip
Executive Summary
Vectura has boosted its finances and investor sentiment by signing a worldwide non-exclusive licensing agreement with GlaxoSmithKline for patents on Vectura's dry powder formulation technology for inhaled medicines.